Comparative outcome analysis of hydroxychloroquine/chloroquine, remdesivir and standard of care treatment against COVID-19 infection
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20205550Keywords:
nCoV-19, COVID-19, Hydroxychloroquine/chloroquine, Remdesivir, Standard of careAbstract
This study aimed to compare the efficacy and safety of hydroxychloroquine/chloroquine (HCQ/CQ), remdesivir and standard of care treatment (SOC) in patients with nCoV-19 based on the RCTs available in the literature. We conducted a cumulative review of all the RCTs published for the treatment of nCoV-19. Analysis for odds of patient recovery on HCQ/CQ, remdesivir and SOC treatment was accomplished and recovery was expressed as undetectable viral RNA levels. Total sample size in our analysis was 978 from six RCTs, in which nCoV-19 positive patients treated with HCQ/CQ, remdesivir and SOC were 166,560 and 252, respectively. SOC treatment showed increase in 2-fold of patients’ recovery as compared to the HCQ/CQ group (p=0.0006). Further, patients reported 1.5-3-fold increase in adverse events in remdesivir and HCQ/CQ group as compared to SOC group (p=0.0016 and p<0.0001). Our finding suggests remdesivir or HCQ/CQ ensures no benefit over SOC treatment, which may be attributed to the adverse events exhibited by remdesivir, or inefficacy of HCQ/CQ.
References
Available at: https://www.who.int/newsroom/detail/27-04-2020-who-timeline---covid-19. Accessed on 10 August 2020.
Available at: http://www.who.int/docs/default source/coronaviruse/situation-reports/20200620- covid-19-sitrep-152.pdf?sfvrsn=83aff8ee_2. Accessed on 10 August 2020.
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;323(18):1824-36.
Zheng S, Fan J, Yu F. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, retrospective cohort study. BMJ. 2020;369:m1443.
Hamid S, Mir MY, Rohela GK. Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics). New Microbes New Infect. 2020;35:100679.
Borba MGS, Val FFA, Sampaio VS. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open. 2020;3:e208857.
Cao B, Wang Y, Wen D. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382:1787-99.
Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569-78.
Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020;383(19):1827-37.
Huang M, Tang T, Pang P, Li M, Ma R, Lu J et al. Treating COVID-19 with Chloroquine. J Mol Cell Biol. 2020;12:322-5.
Gao J, Tian Z and Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14:72-3.
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020:56(1):105949.
Jacobs M, Rodger A, Bell DJ, Bhagani S, Cropley I, Filipe F et al. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet. 2016;388:498-503.
Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020;382:929-36.
Team C-I. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. Nat Med. 2020;26(6):861-8.
